Contact : Dr. Ronald Frank ( Coordinator ) office@eu-openscreen.eu

1. CONTRIBUTION TO solvethe Grand challenge OF SAFE FOOD PRODUCTION CONTRIBUTION TO solvethe Grand challengeOF healthyaging Identificationofbiologicallyactivecompoundsisexpensiveandhighlydemanding in resourcesandknow-how Requirementsexceedthecapacitiesofmanyinstitutes, andeven countries Coordinationofrequiredresourcesat European levelnecessary Improvementofthequalityofournutrition asthebasisfor a healthierlife Development ofinnovative drugsanddiagnostics • Academia: • Coordinated and well-funded • academic drug-discovery sector needed • De-risking of novel targets for new paradigms; • Development of novel technologies and methods • Addressing the challenge of personalised medicine • Pharmaceuticalindustry: • Streamlineddrugdevelopmentandmarketingestablished • Risk aversion focus on „established targets“ • Extensive expertise in, and emphasis on, later development stages IMPROVEMENT OF CURRENT RESEARCH LANDSCAPE • Ex: Studyingmetabolicpathways: • Increased knowledge on the metabolism of food ingredients • Improvement of immune and intestinal functions (prebiotics) • Ex: Studyingthebiologicaleffectsof: • Food additives anddietarysupplements • „neutraceuticals“ (foodwhichisfortifiedorenrichedwithcomplementarynutrientsordrugs) • Implementation Plan • ESFRI Roadmap: ESFRI considers EU-OPEN-SCREEN as vital to the excellence of research and innovation in Europe and included it to the “European Roadmap of Research Infrastructures”. • PreparatoryPhase (3 years): Preparationof a master plan describing in detailthemodeofconstructionandoperation. EU funding, 3.7 M€. • Construction Phase (1 year): Constructionofinfrastructure (existingandnewsites). National funding. • Operation Phase: Run theinfrastructureandprovideaccesstoresearchers. Diverse fundingsources. • EU-OPENSCREEN: • Aim: Establishment of a distributed pan-European infrastructure of open-access screening platforms for chemical biology in all areas of the life sciences • Objectives: Integration of high-throughput screening platforms, chemical libraries, chemical expertise and resources for hit optimization, bio-informatics support, and a database • Impact: Addressing the Grand Challenges, e.g. aging societies, public health, food security • EU-OPENSCREEN will accelerate the generation of knowledge about the bioactivities of chemicals • EU-OPENSCREEN will address non-validated targets, unlike commercial screening platforms and the pharmaceutical industry • Consortium: 17 research groups in 12 European countries European networK Appl. Research Appl. Research EU- OPENSCREEN GAP • Oslo University • Umeå University • FIMM, Helsinki • DTU, Copenhagen • NKI National Cancer Institute, Amsterdam • FVB Research Association Berlin • Helmholtz Centre for Infection Research (HZI),Braunschweig • BMBF Federal Ministry for Education and Research, Berlin • Gottfried Wilhelm Leibniz Scientific Community • Helmholtz Association of German Research Centres • EMBL-EBI European Molecular Biology Laboratory, Heidelberg • Institute for Medical Biology of the Polish Academy of Sciences, Łódź • Institute of Molecular Genetics, Prague • CeMM Research Centre for Molecular Medicine of the Austrian Academy of Science, Vienna • CNRS Centre Nationale de la Recherche Scientifique • PCB Barcelona Science Park • CISI Centre for Biomolecular Interdisciplinary Studies and Industrial Applications, Milan Basic Research Basic Research Situation Today Ideal Situation ESFRI Roadmap Preparation Construction Operation • EU-OPENSCREEN aims at: • extending the basis for innovation and • bridging the gap between basic and applied research Currentpartners Associated members CoordinationCentreat FMP Berlin OBJECTIVES New probesforbiology & drugs ADVANTAGES TO RESEARCHERS BENEFITS FOR ALL AREAS OF THE LIFE SCIENCES Acceleratedgenerationofknowledgenot only in pharmaceuticalresearch, but in allareasofTHE lifescieNces. European open-access researchinfrastructure Access tosharedresources(personnel, technology, equipment, know-howforscreening, compoundprofiling,chemicaloptimisation, ADMETox, …) Extensive technicalresourcesandwiderangeofavailablechemicalcompounds Facilitationoftheidentificationofmoleculartoolsfortheelucidationofmetabolicandsingallingpathways Acceleratedrealisationofscientificresearchprojects Medicine European open-access researchinfrastructure Nutrition Wider rangeofmethodsandassays Compoundlibrary(severalhundredthousandcompounds) Environment Distributed screeningcentresandchemicalfacilities, operating high-end equipment Collectionofgeneratedknowledge in a central, open-access database Agriculture Central database(results, assayprotocol, chemicalinformation) Efficientcoordinationat European level Increasedavailabilityofinformationthroughexchangebetweeninstitutions Biotechnology Joint trainingandeducationprograms Common standards Common standards Efficienttrainingof all staff Harmonised legal framework • Chemical Biology • Systematicapplicationofsmallmoleculesasmolecularprobesfortheelucidationofbiologicalprocesses • Chemical toolshaveuniqueadvantagesandcomplementclassic molecularbiologymethods, such asmutagenesisor RNA interference: • Chemical probescanbeapplied in a time, doseandspaticallycontrollablemanner • Site-specificinhibitionofmultifunctionalproteins • Broadinhibitionofproteinfamilies • Multiple knockdowns • Small moleculesarecandidatesfornewdrugsandproducts • Directtransfertoin vivo-studies 13 Research Infrastructuresprojects in Biological and Medical Sciences INNOVATION CHAIN WITHOUT GAP EU-OPENSCREEN is an essential component in thenetworkof European researchinfrastructures(RI) andallowsfor a multidisciplinarycollaboration in Europe. The Biological & Medical Sciences RI (BMS-RI) supportdevelopmentsfrombasicresearchtoapplication. Biological Sciences Biological Resources & Production Systems Medical Sciences • The EU-OPENSCREEN database will beconnectedtootherbiologicaldatabasesthroughELIXIR • PharmacologicallyactivecompoundscanbedevelopedfurtherthroughEATRIS andECRIN • Cell-linesandanimalmodelsforbioprofilingofcompoundsareavailablethroughBBMRI andINFRAFRONTIER ELIXIR BBMRI ECRIN INFRAFRONTIER EATRIS INSTRUCT EMBRC EU-OPENSCREEN ERINHA Euro-BioImaging MIRRI ISBE ANAEE Contact: Dr. Ronald Frank (Coordinator) office@eu-openscreen.eu